341 related articles for article (PubMed ID: 30217118)
1. Efficacy of 4-year denosumab treatment alone or in combination with teriparatide in Japanese postmenopausal osteoporotic women.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2019 Jul; 29(4):676-681. PubMed ID: 30217118
[No Abstract] [Full Text] [Related]
2. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
[TBL] [Abstract][Full Text] [Related]
3. Two-year clinical outcome of denosumab treatment alone and in combination with teriparatide in Japanese treatment-naive postmenopausal osteoporotic women.
Nakamura Y; Suzuki T; Kamimura M; Ikegami S; Murakami K; Uchiyama S; Taguchi A; Kato H
Bone Res; 2017; 5():16055. PubMed ID: 28690911
[TBL] [Abstract][Full Text] [Related]
4. Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial.
Leder BZ; Tsai JN; Uihlein AV; Burnett-Bowie SA; Zhu Y; Foley K; Lee H; Neer RM
J Clin Endocrinol Metab; 2014 May; 99(5):1694-700. PubMed ID: 24517156
[TBL] [Abstract][Full Text] [Related]
5. Response to Therapy With Teriparatide, Denosumab, or Both in Postmenopausal Women in the DATA (Denosumab and Teriparatide Administration) Study Randomized Controlled Trial.
Leder BZ; Tsai JN; Neer RM; Uihlein AV; Wallace PM; Burnett-Bowie SA
J Clin Densitom; 2016; 19(3):346-51. PubMed ID: 26900146
[TBL] [Abstract][Full Text] [Related]
6. Denosumab significantly improves bone mineral density with or without bisphosphonate pre-treatment in osteoporosis with rheumatoid arthritis : Denosumab improves bone mineral density in osteoporosis with rheumatoid arthritis.
Nakamura Y; Suzuki T; Kato H
Arch Osteoporos; 2017 Sep; 12(1):80. PubMed ID: 28936606
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
8. Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial.
Tsai JN; Lee H; David NL; Eastell R; Leder BZ
Lancet Diabetes Endocrinol; 2019 Oct; 7(10):767-775. PubMed ID: 31447409
[TBL] [Abstract][Full Text] [Related]
9. Combined teriparatide and denosumab therapy accelerates spinal fusion following posterior lumbar interbody fusion.
Ide M; Yamada K; Kaneko K; Sekiya T; Kanai K; Higashi T; Saito T
Orthop Traumatol Surg Res; 2018 Nov; 104(7):1043-1048. PubMed ID: 30179720
[TBL] [Abstract][Full Text] [Related]
10. Vitamin D and Calcium Addition during Denosumab Therapy over a Period of Four Years Significantly Improves Lumbar Bone Mineral Density in Japanese Osteoporosis Patients.
Suzuki T; Nakamura Y; Kato H
Nutrients; 2018 Feb; 10(3):. PubMed ID: 29495518
[TBL] [Abstract][Full Text] [Related]
11. Circulating noggin levels following treatment with denosumab or teriparatide in postmenopausal women with low bone mass.
Anastasilakis AD; Polyzos SA; Makras P; Rauner M; Sonnleitner L; Hawa G; Tsourdi E; Yavropoulou MP; Missbichler A; Terpos E
J Musculoskelet Neuronal Interact; 2019 Sep; 19(3):253-257. PubMed ID: 31475931
[TBL] [Abstract][Full Text] [Related]
12. Effects of bone remodeling agents following teriparatide treatment.
Burkard D; Beckett T; Kourtjian E; Messingschlager C; Sipahi R; Padley M; Stubbart J
Osteoporos Int; 2018 Jun; 29(6):1351-1357. PubMed ID: 29541794
[TBL] [Abstract][Full Text] [Related]
13. Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial.
Tsai JN; Uihlein AV; Lee H; Kumbhani R; Siwila-Sackman E; McKay EA; Burnett-Bowie SA; Neer RM; Leder BZ
Lancet; 2013 Jul; 382(9886):50-6. PubMed ID: 23683600
[TBL] [Abstract][Full Text] [Related]
14. Importance of prompt antiresorptive therapy in postmenopausal women discontinuing teriparatide or denosumab: The Denosumab and Teriparatide Follow-up study (DATA-Follow-up).
Leder BZ; Tsai JN; Jiang LA; Lee H
Bone; 2017 May; 98():54-58. PubMed ID: 28286299
[TBL] [Abstract][Full Text] [Related]
15. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
[TBL] [Abstract][Full Text] [Related]
16. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
17. Teriparatide and denosumab combination therapy and skeletal metabolism.
Idolazzi L; Rossini M; Viapiana O; Braga V; Fassio A; Benini C; Kunnathully V; Adami S; Gatti D
Osteoporos Int; 2016 Nov; 27(11):3301-3307. PubMed ID: 27250971
[TBL] [Abstract][Full Text] [Related]
18. Combination and sequential treatment in women with postmenopausal osteoporosis.
Anastasilakis AD; Polyzos SA; Yavropoulou MP; Makras P
Expert Opin Pharmacother; 2020 Mar; 21(4):477-490. PubMed ID: 31990595
[No Abstract] [Full Text] [Related]
19. Vitamin D and Calcium Are Required during Denosumab Treatment in Osteoporosis with Rheumatoid Arthritis.
Nakamura Y; Suzuki T; Yoshida T; Yamazaki H; Kato H
Nutrients; 2017 Apr; 9(5):. PubMed ID: 28445420
[TBL] [Abstract][Full Text] [Related]
20. Switching to Denosumab or Bisphosphonates After Completion of Teriparatide Treatment in Women With Severe Postmenopausal Osteoporosis.
Kocjan T; Rajic AS; Janez A; Vidmar G; Orehek N; Marc J; Ostanek B
Endocr Pract; 2021 Sep; 27(9):941-947. PubMed ID: 34111556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
